Access to therapy is part of the protection of the constitutional order: Peter Bely spoke at the SPIEF session on intellectual property
28.06.2022
28.06.2022
Sorafenib-Promomed became the fifth drug in the company's antitumor portfolio, which previously included drugs for the treatment of widespread cancers such as myeloma, non-small cell lung cancer and prostate cancer.

Sorafenib belongs to targeted drugs, it is a low-molecular-weight multikinase inhibitor. This drug is used for the treatment of renal cell carcinoma, liver cell carcinoma, as well as differentiated thyroid cancer (resistant to radioactive iodine).
The effectiveness of Sorafenib has been clinically proven. The drug's action is aimed at blocking certain signals from tumor cells, which prevents their further growth, and also prevents the growth of blood vessels that deliver oxygen to the tumor.
The development and production of drugs for the treatment of oncological diseases is an important strategic direction of the Promomed Group of companies, focused on solving significant medical problems, saving and significantly improving the quality of life of patients.
Sorafenib-Promomed will be available in the form of tablets with a dosage of 200 mg, which corresponds to standard application schemes.
Like most medicines produced by Promomed Group, this drug is included in the list of VED.
Stay informed
Stay informed
Get the most interesting news and publications first!
Sent successfully!
Press office
To request a press release or interview, please contact our press office